Skip to search formSkip to main contentSkip to account menu

CMAB009

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from…
BackgroundThe 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic… 
2017
2017
A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer…
3513Background: More efficient second line treatment regimen for mCRC is urgently needed. CMAB009, a recombinant human/mouse… 
2011
2011
Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors
In the present study, we conducted a Phase 1 study of a recombinant anti-EGFR monoclonal antibody (CMAB009) that has the same… 
2011
2011
[Phase I study of anti-EGFR monoclonal antibody (CMAB009) in patients with advanced cancer].
OBJECTIVE To characterize the safety profiles and serum pharmacokinetic effects of anti-epidermal growth factor receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)